SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
K. N. Chi
Consultant or Advisory Role - Oncogenex (U); Teva (U)
Research Funding - Teva
J. S. De Bono
Employment or Leadership Position - Institute of Clinical Research
Research Funding - Teva
C. S. Higano
Research Funding - Teva